SEC Form SC 13G filed by Lantern Pharma Inc.

$LTRN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $LTRN alert in real time by email
SC 13G 1 formsc13g.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Amendment No. *)

 

Under the Securities Exchange Act of 1934

 

Lantern Pharma Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

51654W101

(CUSIP Number)

 

November 8, 2022

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)

 

☒ Rule 13d-1(c)

 

☐ Rule 13d-1(d)

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

 

 

 

 
 

 

CUSIP No. 51654W101

 

1.

NAMES OF REPORTING PERSONS

ProPhase Labs, Inc.

 

 
2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a) ☐ (b) ☐

 

 
3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

910,000

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

910,000

8.

SHARED DISPOSITIVE POWER

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

910,000

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.4% (1)

12.

TYPE OF REPORTING PERSON (see instructions)

CO

   
(1) Based on 10,857,040 shares outstanding as of November 1, 2022 according to the quarterly report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on November 7, 2022.

 

 
 

 

Item 1.

 

(a) Name of Issuer:

 

Lantern Pharma Inc. (the “Issuer”)

 

(b) Address of Issuer’s Principal Executive Offices:

 

1920 McKinney Avenue, 7th Floor Dallas, Texas 75201

 

Item 2.

 

(a)-(c) Name, Address and Citizenship of Reporting Persons

 

ProPhase Labs, Inc.

711 Stewart Ave, Suite 200

Garden City, New York 11530

Place of Incorporation: Delaware

 

(d) Title of Class of Securities

 

Common Stock, $0.0001 par value per share (“Common Stock”)

 

(e) CUSIP Number

51654W101

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

Item 4. Ownership.

 

(a) Amount Beneficially Owned:

 

Please refer to items 5-9 of the cover pages attached hereto for the amounts beneficially owned by the reporting persons as of November 21, 2022.

 

(b) Percent of Class

 

Please refer to item 11 of the cover pages attached hereto

 

(c) Number of shares as to which such person has:

 

Please refer to items 5-8 of the cover pages attached hereto

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

 
 

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 
 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: November 21, 2022 PROPHASE LABS, INC.
     
  By: /s/ Ted Karkus
  Name: Ted Karkus
  Title: Chairman of the Board and Chief Executive Officer

 

 

 

Get the next $LTRN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LTRN

DatePrice TargetRatingAnalyst
3/11/2022$34.00 → $36.00Buy
HC Wainwright & Co.
11/2/2021$32.00 → $34.00Buy
HC Wainwright & Co.
10/7/2021$32.00Buy
HC Wainwright & Co.
More analyst ratings

$LTRN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

    Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability. The application received a favorable PCT search report indicating no significant prior art, substantially strengthening its path to approval. The technology has demonstrated to-date exceptional performance in predicting BBB permeability across a wide range of chemical compounds, processing up to 100,000 molecul

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

    Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR® AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs). The global ADC market is projected to reach $30.4 billion by 2028, growing at a CAGR of 41.7%, with several recently approved ADCs achieving blockbuster status with annual sales exceeding $1 billion. Major biotech and pharmaceutical companies have recently completed ADC-focused acquisitions valued at over $10 billion, highlighting the sect

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

    Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung cancer cases in Taiwan occur in never-smokers. Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The enrollm

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LTRN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LTRN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LTRN
SEC Filings

See more

$LTRN
Leadership Updates

Live Leadership Updates

See more
  • Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

    DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LTRN
Financials

Live finance-specific insights

See more
  • Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

    Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients continue to be enrolled in the US. The Harmonic™ Trial has been expanded to both Japan and Taiwan with an expected 10 sites in East Asia; 5 in each country where the population of never-smokers is 33 to 35 percent of new cases in NSCLC. Phase 1 clinical trials for both synthetic lethal drug candidates, LP-18

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

    Webcast to be held Thursday, November 7th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the third quarter ended September 30, 2024 and provide guidance on upcoming milestones, cl

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

    Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development. Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety lead-in cohort. Issued a Certificate of Patent by the Japanese Patent Office directed to Lantern Pharma's drug candidate LP-284, including claims covering the new molecular entity. Phase 1 clinical trials for both synthetic lethal drug candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and over 40 patients

    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$LTRN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more